Key Takeaways DGX posted strong Q1 growth across brain health, oncology and women's health diagnostics. Strategic deals like LifeLabs and PathAI Diagnostics strengthen DGX's core and adjacent markets. DGX targets 3% annual cost savings with automation, Project Nova and GenAI partnerships.Quest Diagnostics Inc. (DGX) is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company’s growth strategy includes pursuing value-creating, strate ...

Quest Diagnostics (DGX) FY Conference June 03, 2025 11:00 AM ET Speaker0 Thanks again for joining us at this year's William Blair Growth Stock Conference. This morning, we're very pleased to have the team from Quest Diagnostics joining us here. We have the CEO, Jim Davis from Investor Relations, Sean Bevek here in the front row. Format for today will be a thirty minute presentation in this room, then we'll go to the breakout afterwards, which is an ad in the Adler Room on the Second Floor. And then for comp ...

Core Insights - Myriad Genetics will present data from seven new research studies at the 2025 ASCO Annual Meeting, focusing on Molecular Residual Disease (MRD) clinical outcomes from the MONSTAR-SCREEN-3 study [1][3] - The company emphasizes its commitment to advancing precision oncology through its comprehensive portfolio of genetic and tumor genomic testing solutions [1][3][7] MRD Studies - An oral abstract titled "Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel" will be presented, showcasing successful ctDNA detection across over 100 patients with a baseline detection rate of 100% [2] - The interim results indicate the ability to detect tumor fractions as low as 0.0001% and provide a lead time in detecting recurrence compared to imaging [2] Myriad Oncology Portfolio - Myriad Oncology will unveil a new brand identity at the ASCO meeting, highlighting its streamlined approach to germline testing, tumor profiling, and companion diagnostic testing [4] - Upcoming product innovations include the integration of Myriad's oncology portfolio with Flatiron's OncoEMR and Epic cloud-based platforms, enhancing workflow for clinicians [6] Product Innovations - The Precise MRD test, based on whole genome sequencing, is designed to monitor tumor-specific variants and is expected to launch commercially in 2026 [11] - The Prolaris Prostate Cancer Prognostic Test, utilizing AI technology, is anticipated to launch in early 2026, providing clinicians with data-driven insights for treatment decisions [11] - An expanded MyRisk Gene Panel is set to launch later this year, incorporating more clinically actionable genes based on national guidelines [11]

Quest Diagnostics (DGX) Q1 2025 Earnings Call April 22, 2025 08:30 AM ET Company Participants Shawn Bevec - VP of IRJames Davis - Chairman, CEO & PresidentSam Samad - Executive VP & CFOKevin Caliendo - Managing DirectorPatrick Donnelly - Managing DirectorNoah Kava - Equity Research AssociateMichael Ryskin - Managing Director Conference Call Participants Luke Sergott - AnalystElizabeth Anderson - AnalystMichael Cherny - Senior Managing Director & Senior Research AnalystPito Chickering - AnalystDavid Westenbe ...